Akute kindliche Ophthalmoplegie (Miller-Fisher-Syndrom): ein interessanter Fall

Einleitung

Das Miller-Fisher-Syndrom wurde 1956 erstmalig bei Patienten mit akuter Ophthalmoplegie, Ataxie und fehlenden Sehnenreflexen (Areflexie) beschrieben [1]. Es stellt eine Variante des Guillain-Barré-Syndroms dar und manifestiert sich selten auch im Kindesalter. Wir berichten über einen jungen Patienten mit Miller-Fisher-Syndrom, der mit Immunglobulinen und Methylprednisolon behandelt wurde.

• Literatur

• 1 Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956; 255: 57-65
• 2 Berlit P, Rakicky J. The Miller Fisher syndrome. Review of the literature. J Clin Neuroophthalmol 1992; 12: 57-63
• 3 Ammache Z, Afifi AK, Brown CK. et al. Childhood Guillain-Barré syndrome: clinical and electrophysiologic features predictive of outcome. J Child Neurol 2001; 16: 477-483
• 4 Mori M, Kuwabara S, Fukutake T. et al. Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology 2007; 68: 1144-1146
• 5 Schessl J, Luther B, Kirschner J. et al. Infections and vaccinations preceding childhood Guillain-Barré syndrome: a prospective study. Eur J Pediatr 2006; 165: 605-612
• 6 Lee JH, Sung IY, Rew IS. Clinical presentation and prognosis of childhood Guillain-Barré syndrome. J Paediatr Child Health 2008; 44: 449-454
• 7 Ito M, Kuwabara S, Odaka M. et al. Bickerstaffʼs brainstem encephalitis and Fisher syndrome form a continuous spectrum. J Neurol 2008; 255: 674-682
• 8 Buchwald B, Weishaupt A, Toyka KV. et al. Pre- and postsynaptic blockade of neuromuscular transmission by Miller-Fisher syndrome IgG at mouse motor nerve terminals. Eur J Neurosci 1998; 10: 281-290
• 9 Koga M, Gilbert M, Li J. et al. Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry. Neurology 2005; 64: 1605-1611
• 10 Schessl J, Koga M, Funakoshi K. et al. Prospective study on anti-ganglioside antibodies in childhood Guillain-Barré syndrome. Arch Dis Child 2007; 92: 48-52
• 11 Chiba A, Kusunoki S, Obata H. et al. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 1993; 43: 1911-1917
• 12 Li H, Yuan J. Miller Fisher syndrome: toward a more comprehensive understanding. Chin Med J (Engl) 2001; 114: 235-239
• 13 Irvine AT, Tibbles J. Treatment of Fisherʼs variant of Guillain Barré syndrome by exchange transfusion. Can J Neurol Sci 1981; 8: 49-50
• 14 Korinthenberg R, Schessl J, Kirschner J. Clinical presentation and course of childhood Guillain-Barré syndrome: a prospective multicentre study. Neuropediatrics 2007; 38: 10-17
• 15 Anthony SA, Thurtell MJ, Leigh RJ. Miller Fisher syndrome mimicking ocular myasthenia gravis. Optom Vis Sci 2012; 89: e118
• 16 Mori M, Kuwabara S, Fukutake T. et al. Clinical features and prognosis of Miller Fisher syndrome. Neurology 2001; 56: 1104-1106
• 17 Tasdemir HA, Dilber C, Kanber Y. et al. Intravenous immunoglobulin for Guillain-Barré syndrome: how effective?. J Child Neurol 2006; 21: 972-974
• 18 Arakawa Y, Yoshimura M, Kobayashi S. et al. The use of intravenous immunoglobulin in Miller Fisher syndrome. Brain Dev 1993; 15: 231-233
• 19 Lehmann HC, Meyer zu Horste G, Hartung HP. et al. Pathogenesis and treatment of immune-mediated neuropathies. Ther Adv Neurol Disord 2009; 2: 261-281
• 20 Halstead SK, Zitman FMP, Humphreys PD. et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008; 131: 1197-1208